John H . Farley, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Affiliate Professor

Book, Chapter/Section

• Emerging Therapeutic Targets in Ovarian Cancer
  Farley John, Birrer Michael J., Discovery of Novel Targets [Book Chapter] 2011
• Cancer Treatment and Research
  Farley John, Birrer Michael J., Novel Therapeutic Targets [Book Chapter] 2009
• Pathway Analysis for Drug Discovery
  Farley John, Birrer Michael J, Ozbun Laurent L, Whole‐Genome Expression Profiling of Papillary Serous Ovarian Cancer: Activated Pathways, Potential Targets, and Noise [Book Chapter] 2008

Publications

• Gynecologic oncology
  Dukes Danielle, Wang Runzhi, Diagne Yaye Fatou, Garr Logan, Kang Paul, Loaiza Arturo, Yost Connor, Sookram Janhvi, Huh Warner, Farley John, Yost McKenna, York Mikaela, Owaka Jessica, Guideline-anchored retrieval-augmented generation outperforms baseline and literature-only configurations in gynecologic oncology decision support: A pre-integration benchmark
  211, p. 224 2026
• American Society of Clinical Oncology educational book
  Farley John H, Horowitz Neil S, Fujiwara Keiichi, Lee Jung Yun, Tan David S P, Unique Considerations in Rare Gynecologic Tumors: Gestational Trophoblastic Neoplasia, Germ Cell Tumors, and Clear Cell Ovarian Cancers
  46:3, p. e520622 2026
• Gynecologic oncology
  Dukes Danielle, Farley John, Yost McKenna, Yost Connor, Wang Runzhi, Garr Logan, Diagne Yaye Fatou, Osborn Sarah, Source discipline matters: Guideline-anchored large language model beats open evidence for decision support in gynecologic oncology
  208, p. S137 - S138 2026
• Gynecologic oncology
  Dukes Danielle, Yost Connor, Diagne Yaye Fatou, Shah Vishaya, Premkumar Agnes, Kang Paul, Wang Runzhi, Lee Joseph, Powell Anathea, Farley John, Thawani Nitika, Surgical debulking is an important treatment for Krukenberg tumors (KTs) arising in heavily pre-treated metastatic colorectal cancer (mCRC)
  208, p. S304 - S305 2026
• Journal for immunotherapy of cancer
  Patel Sandip P, Azenkot Tali, Wagner Michael J, Othus Megan, Chae Young K, Chen Helen X, Threlkel Sara, Farley John H, Magner Christine M, Sharon Elad, Ryan Christopher W, Blanke Charles, Kurzrock Razelle, Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of D ual A nti-CTLA-4 and Anti-PD-1 blockade in R are T umors (DART) SWOG S1609 (Cohort 38)
  13:10, p. e013147 2025
• Cancer
  Lin Ken Y, Farley John H, Putting a spotlight on current chemotherapeutic options for recurrent ovarian clear cell carcinoma
  131:19, p. e70112 2025
• Gynecologic oncology
  Pothuri Bhavana, Muir Michele, Hurteau Jean, Farley John, Lightfoot Michelle, Dewdney Summer, Castellano Tara, Chan John, Paskett Electra, Ghamande Sharad, Identifying and breaking racial and ethnic barriers: Enhancing access and equity in the care of patients with gynecologic malignancies
  200, p. 76 - 77 2025
• Gynecologic oncology
  Pothuri Bhavana, Muir Michele, Dewdney Summer, Hurteau Jean, Farley John, Lightfoot Michelle, Castellano Tara, Chan John, Ghamande Sharad, Rimel B.J., Paskett Electra, Asante-Facey Al, Stasenko Marina, Identifying and breaking barriers for the treatment of gynecologic malignancies within the lesbian, gay, bisexual, transgender, queer/questioning, intersex and/or asexual community
  200, p. 290 - 291 2025
• Gynecologic oncology reports
  Pothuri Bhavana, Muir Michele, Hurteau Jean, Farley John, Lightfoot Michelle D.S., Dewdney Summer, Castellano Tara, Stasenko Marina, Chan John K., Ghamande Sharad, Asante-Facey Al, Rimel B.J., Paskett Electra D., Identifying and breaking barriers: Addressing disparities in the care of patients with gynecologic cancers, p. 101799 2025
• Cancer
  Ebott Jasmine, Chapman-Davis Eloise, Hines Jeffrey F, Grant Kelsea R, Farley John, Stasenko Marina, Gender equity gap persists, addressing the root cause through the lens of gynecologic oncology: An evidenced-based review
  131:9, p. e35843 2025
• Gynecologic oncology
  Kopelman Zachary A., Phippen Neil T., Tumas Jordyn, Winkler Stuart S., Kucera Calen W., Chan John K., Jones Nathaniel L., Rocconi Rodney P., Farley John H., Darcy Kathleen M., Maxwell G. Larry, Secord Angeles Alvarez, Walker Joan L., Tian Chunqiao, Tarney Christopher M., Hope Erica R., Jokajtys Suzanne, Richardson Michael T., Kapp Daniel S., Hamilton Chad A., Leath Charles A., Fleming Gini F., Bateman Nicholas W., Conrads Thomas P., Cosgrove Casey M., Powell Matthew A., Klopp Ann, Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials
  183, p. 103 - 114 2024
• Gynecologic oncology
  Kucera Calen W., Darcy Kathleen M., Chappell Nicole P., Tian Chunqiao, Richardson Michael T., Wenzel Lari, Sitler Collin A., Klopp Ann, Phippen Neil T., Maxwell G. Larry, Tarney Christopher M., Hamilton Chad A., Kapp Daniel S., Leath Charles A., Chan John K., Casablanca Yovanni, Rojas Christine, Jones Nathaniel L., Rocconi Rodney P., Farley John H., Conrads Thomas P., O'Connor Timothy D., Shriver Craig D., Bateman Nicholas W., Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors
  184, p. 224 - 235 2024
• Gynecologic oncology
  Winkler Stuart S, Kucera Calen W, Tarney Christopher M, Chan John K, Liao Cheng-I, Hamilton Chad A, Bateman Nicholas W, Jokajtys Suzanne, Casablanca Yovanni, Powell Matthew A, Farley John, Darcy Kathleen M, Phippen Neil T, Richardson Michael T, Kapp Daniel S, Tian Chunqiao, Leath, 3rd Charles A, Shriver Craig D, Reddy Megan, Cote Michele L, O'Connor Timothy D, Jones Nathaniel L, Rocconi Rodney P, Maxwell G Larry, Conrads Thomas P, Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes
  184, p. 31 2024
• Clin Cancer Res
  Grisham Rachel N, Drill Esther, Vergote Ignace, Banerjee Susana, Kalbacher Elsa, Mirza Mansoor Raza, Iyer Gopa, Romero Ignacio, Vuylsteke Peter, Kristensen Gunnar, Clamp Andrew, Farley John, Ray-Coquard Isabelle, Monk Bradley J, Coleman Robert L, Hilpert Felix, Oza Amit M, Aghajanian Carol, Westermann Anneke, Oehler Martin K, Pignata Sandro, Colombo Nicoletta, Cibula David, Moore Kathleen N, Sehouli Jalid, Del Campo Josep M, Berger Regina, Marth Christian, O'Malley David M, Churruca Cristina, Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
  29:20, p. 4068 - 4075 2023
• Clinical cancer research
  Grisham Rachel N, Oza Amit M, Hilpert Felix, Banerjee Susana, Drill Esther, Vergote Ignace, Coleman Robert L, Romero Ignacio, Vuylsteke Peter, Cibula David, Moore Kathleen N, Del Campo Josep M, Berger Regina, Marth Christian, Kristensen Gunnar, Churruca Cristina, Clamp Andrew, Iyer Gopakumar, Mirza Mansoor Raza, Kalbacher Elsa, Ray-Coquard Isabelle, Monk Bradley J, Aghajanian Carol, Colombo Nicoletta, Westermann Anneke, Oehler Martin K, Pignata Sandro, Sehouli Jalid, O'Malley David M, Farley John, Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer 2023
• Gynecologic oncology reports
  Garg Ruchi, Schink Julian, Buttin Barbara, Elvin Julia, Godbee Natalie, Moran Amber, Doctor Vicki, Sequeira Judy, Farley John, Markman Maurie, Tan Bradord, 6 Racial differences in the mutational landscape of serous endometrial cancer
  44, p. S3 - S4 2022
• Gynecologic oncology reports
  Garg Ruchi, Farley John, Doctor Vicki, Tan Bradord, Sequeira Judy, Markman Maurie, Elvin Julia, Schink Julian, Buttin Barbara, Godbee Natalie, Moran Amber, 37 Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race
  44, p. S19 - S19 2022
• Gynecologic oncology
  Jernigan Amelia, Farley John, Walsh Christine, Report Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
  166:2, p. 207 - 210 2022
• Gynecologic oncology
  Sitler Collin, Tian Chunqiao, Casablanca Yovanni, Phippen Neil, Kucera Calen, Farley John, Hamilton Chad, Chan John, Liao Cheng-I, Shriver Craig, Bateman Nicholas, Conrads Thomas, Maxwell G. Larry, Darcy Kathleen, Do U.S. Screening Guidelines Contribute to Higher Stage and Worse Survival in our Youngest and Oldest Cervical Cancer Patients? (019)
  166, p. S14 - S15 2022
• Journal of clinical oncology
  Schink Julian C., Buttin Barbara, Elvin Julia Andrea, Tan Bradford A., Farley John H., Markman Maurie, Doctor Vicki, Garg Ruchi, Godbee Natalie, Moran Amber, Racial differences in the mutational landscape of serous endometrial cancer
  40:16_suppl, p. 5600 - 5600 2022
• Journal of clinical oncology
  Garg Ruchi, Farley John H., Markman Maurie, Schink Julian C., Buttin Barbara, Elvin Julia Andrea, Godbee Natalie, Moran Amber, Doctor Vicki, Tan Bradford A., Sequeria Judy, Therapeutic implications of mutations in high grade serous ovarian carcinoma when evaluated by race
  40:16_suppl, p. e17590 - e17590 2022
• Journal of clinical oncology
  Schink Julian C., Garg Ruchi, Elvin Julia Andrea, Godbee Natalie, Moran Amber, Doctor Vicki, Tan Bradford A., Farley John H., Markman Maurie, Mutational landscape of low-grade serous carcinoma of the ovary
  40:16_suppl, p. 5578 - 5578 2022
• The Lancet (British edition)
  Gershenson David M., Connolly Kate, Coleman Robert L., Moore Kathleen N., Banerjee Susana, Secord Angeles Alvarez, O'Malley David M., Slomovitz Brian, Dorigo Oliver, Gaillard Stephanie, Gabra Hani, Hanjani Parviz, Farley John, Herrington C. Simon, Churchman Michael, Ewing Ailith, Hollis Robert L., Huang Helen Q., Carty Karen, Wenzel Lari, Gourley Charlie, Miller Austin, Brady William E., Paul James, Rodgers William, Millan David, Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS) : an international, randomised, open-label, multicentre, phase 2/3 trial
  399:10324, p. 541 - 553 2022
• Cancer epidemiology
  Rhoades Dorothy A., Schwartz Stephen M., Farley John, Zhang Ying, Malloy Kimberly M., Wang Wenyu, Best Lyle G., Lee Elisa, Ali Tauqeer, Yeh Fawn, Rhoades Everett R., Howard Barbara V., Cancer mortality in a population-based cohort of American Indians – The strong heart study
  74, p. 101978 - 101978 2021
• Journal of clinical oncology
  Grisham Rachel N., Westermann Anneke M., Aghajanian Carol, Mirza Mansoor Raza, Scambia Giovanni, Vergote Ignace, Banerjee Susana N., Drill Esther N., Fabbro Michel, Hilpert Felix, Romero Ignacio, Coleman Robert L., Oza Amit M., Moore Kathleen N., O'Malley David M., Boyd Adam P., Cantey-Kiser Jean, Farley John H., Colombo Nicoletta, Monk Bradley J., Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)
  39:15_suppl, p. 5519 - 5519 2021
• Gynecologic oncology
  Chase Dana M., Salani Ritu, Farley John, Torres Tara, Stone Jeff, Unwittingly biased: A note to gynecologic cancer providers
  160:3, p. 646 - 648 2021
• Gynecologic oncology
  Brooks Sandra E., Farley John H., Davis Eloise Chapman, Disparities in pap smear screening follow up: A catalyst for collective action vs. collective despair
  160:2, p. 361 - 363 2021
• Gynecologic oncology
  Crane E.K., Brown J., Ramos P., Farley J.H., Naumann R.W., Tait D.L., Higgins R.V., Molecular profiling in a large cohort of gynecologic neuroendocrine tumors
  159, p. 262 - 262 2020
• Gynecologic oncology
  Brown J., Chen W., Ramos P., ElNaggar A.C., Farley J.H., Covens A.L., Herzog T.J., Crane E.K., Arguello D., Feasibility of a platform trial in rare gynecologic cancers based on molecular analysis
  159, p. 144 - 145 2020
• Gynecologic oncology
  Tewari Krishnansu S., DiSilvestro Paul A., Powell Matthew, Randall Leslie M., Farley John, Rubin Stephen C., Monk Bradley J., Sill Michael W., Coleman Robert L., Aghajanian Carol, Mannel Robert, BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY
  159:1, p. 79 - 87 2020
• Gynecologic oncology
  Farley John H, Lee Nita K, Hines Jeffrey, Brooks Sandra E, Nair Navya, Chapman-Davis Eloise, Brown Carol L, Doll Kemi M, Sullivan Ellen J, Promoting health equity in the era of COVID-19
  158:1, p. 25 - 31 2020
• Journal of clinical oncology
  Brown Jubilee, Crane Erin, Farley John H., Herzog Thomas J., Chen Wangjuh, Covens Al, Arguello David, Ramos Pilar, ElNaggar Adam, Feasibility of a platform trial based on molecular analysis in rare gynecologic cancers
  37:15_suppl, p. e14585 - e14585 2019
• Gynecologic oncology
  Konstantinopoulos Panagiotis A., Armstrong Amy, Brady William E., Farley John, Uyar Denise S., Gershenson David M., Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
  150:1, p. 9 - 13 2018
• Gynecologic oncology
  Oliver Kate E., Brady William E., Birrer Michael, Burger Robert A., Copeland Larry J., Tewari Krishnansu, Gershenson David M., Fleming Gini, Mutch David G., Stehman Frederick B., Argenta Peter A., Mannel Robert S., Secord Angeles Alvarez, Stephan Jean-Marie, Rose Peter G., Armstrong Deborah K., Bookman Michael A., Farley John H., Muggia Franco M., An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
  147:2, p. 243 - 249 2017
• Gynecologic oncology
  Moreno A., Vo Elise, Bhattarai B., Patel S., Farley J., Willmott L., Monk B., Chase D., Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy
  147:1, p. 203 - 203 2017
• Gynecologic oncology
  Barnes Dominique, Monk Bradley J., Chase Dana, Shields Kristin M., Willmott Lyndsay J., Farley John, Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention
  147:1, p. 215 - 215 2017
• Gynecologic oncology
  Barnes Dominique, Willmott Lyndsay J., Farley John, Monk Bradley J., Chase Dana, Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients?
  147:1, p. 215 - 215 2017
• Hematological oncology
  Biasoli I., Praxedes M., Franceschi F., Chiattone C.S., Baioccchi O., Pagnano K., Farley J., Boquimpani C., Sola C.B., Clementino N., Perini G.F., Luminari S., Morais J., Spector N., Tabacof J., Steffenello G., Soares A., Milito C., Souza C., Castro N., Delamain M., Simoes B.P., Gaiolla R., Silveira T., Solza C., Treatment outcomes for Hodgkin's lymphoma patients aged 60 and older: A report from the Brazilian prospective Hodgkin's lymphoma registry
  35:S2, p. 308 - 309 2017
• Cancer
  Dalton H. J., Farley John H., Racial Disparities in Cervical Cancer: Worse than we Thought
  123:6, p. 915 - 916 2017
• European journal of gynaecological oncology
  Niu J., Farley J., Markman M., Kundranda M. N., Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer
  38:1, p. 40 - 44 2017
• Gynecologic oncology research and practice
  Minion Lindsey E., Chase Dana M., Farley John H., Willmott Lyndsay J., Monk Bradley J., Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study
  3:1, p. 4 - 4 2016
• Molecular cancer therapeutics
  Weiss Glen J., Pierog Marci, Blaydorn Lisa, Niu Jiaxin, Farley John H., Sangal Ashish, Khemka Vivek, Abstract A50: Phase Ib/II study of pembrolizumab plus chemotherapy: Initial results of metastatic cancer patients
  14:12_Supplement_2, p. A50 - A50 2015
• Cancer Causes & Control
  Best Lyle G., García-Esquinas Esther, Lee Elisa T., Howard Barbara V., Farley John H., Welty Thomas K., Rhoades Everett R., Umans Jason G., Association of diabetes and cancer mortality in American Indians: the Strong Heart Study
  26:11, p. 1551 - 1560 2015
• Obstetrics and gynecology (New York. 1953)
  Chase Dana M, Farley John H, Craig Christine D, Fedewa Stacey A, Virgo Katherine S, Halpern Michael, Monk Bradley J, Lin Chun Chieh, Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors
  126:4, p. 792 - 802 2015
• Clinical cancer research
  Ramos Pilar, Karnezis Anthony N., Craig David W., Sekulic Aleksandar, Russell Megan L., Hendricks William P.D., Corneveaux Jason J., Farley John H., Roden Richard B.S., Cunliffe Heather E., Huntsman David G., Trent Jeffrey M., Anthony Stephen P., Zismann Victoria L., McEachron Troy A., Salhia Bodour, Prat Jaime, Barrett Michael T., Prentice Leah M., Clarke Blaise A., Pressey Joseph G., Shumansky Karey, Yang Yidong, Shah Sohrab P., Marra Marco A., Kiefer Jeffrey, Abstract POSTER-BIOL-1327: Small cell carcinoma of the ovary, hypercalcemic type displays frequent inactivating germline and somatic mutations in SMARCA4
  21:16_Supplement, p. POSTER-BIOL-1327 - POSTER-BIOL-1327 2015
• Gynecologic oncology
  Shields K.M., Willmott L., Farley J.H., Monk B.J., Chase D., Factors associated with low educational background in uterine cancer patients
  137, p. 123 - 123 2015
• Cancer research (Chicago, Ill.)
  Ramos Pilar, Russell Megan, Karnezis Anthony, Craig David, Sekulic Aleksandar, Hendricks William, Barrett Michael, Shumansky Karey, Yang Yidong, Kiefer Jeffrey, Shah Sohrab, Prentice Leah, Marra Marco, Zismann Victoria, McEachron Troy, Salhia Bodour, Pressey Joseph, Cunliffe Heather, Farley John, Anthony Stephen, Roden Richard, Huntsman David, Trent Jeffrey, Abstract LB-202: The rare, highly malignant small cell carcinoma of the ovary displays common inactivating germline and somatic mutations in the tumor suppressor SMARCA4
  74:19_Supplement, p. LB-202 - LB-202 2014
• Gynecologic oncology research and practice
  Foss Cassandra D, Farley John H, Dalton Heather J, Monk Bradley J, Chase Dana M, Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways
  1:1, p. 4 - 4 2014
• Gynecologic oncology
  Oliver K.E., Brady W.E., Birrer M.J., Fleming G., Farley J.H., Gershenson D.M., An evaluation of progression-free survival (PFS) and overall survival (OS) of ovarian cancer patients with clear cell carcinoma vs serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group (GOG) experience
  133, p. 26 - 27 2014
• Gynecologic oncology
  Craig C., Gibson S.J., Osann K.E., Farley J., Willmott L., Monk B.J., Chase D.M., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study
  131:1, p. 264 - 264 2013
• Gynecologic oncology
  Craig C., Farley J., Monk B., Chase D., Osann K., Gibson S., Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study
  130:1, p. e31 - e32 2013
• Gynecologic oncology
  Miller C., Muggia F., Farley J., Miller A., Hamilton C., Alvarez-Secord A., Havrilesky L., An evaluation of molecular markers that predict maximal surgical cytoreduction: A Gynecologic Oncology Group trial
  130:1, p. e20 - e20 2013
• Gynecologic oncology
  Craig C., Lin C., Fedewa S., Virgo K., Farley J., Monk B., Chase D., Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry
  130:1, p. e163 - e163 2013
• Journal of clinical oncology
  Farley John H., Fleming Gini F., Brady William E., Birrer Michael J., Gershenson David Marc, , An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience
  31:15_suppl, p. 5534 - 5534 2013
• The lancet oncology
  Farley John, Brady William E., Vathipadiekal Vinod, Lankes Heather A., Coleman Robert, Morgan Mark A., Mannel Robert, Yamada S. Diane, Mutch David, Rodgers William H., Birrer Michael, Gershenson David M., Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
  14:2, p. 134 - 140 2013
• Critical Reviews in Oncology/Hematology
  Monk Bradley J., Dalton Heather, Farley John H., Chase Dana M., Benjamin Ivor, Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer
  86:2, p. 161 - 175 2013
• Farley John, Levine Douglas, Birrer Michael, Berchuck Andrew, Molecular Pathogenesis of Gynecologic Cancers 2013
• Clinical ovarian cancer and other gynecologic malignancies
  Boruta David, Birrer Michael J., Farley John, PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
  4:2, p. 70 - 73 2011
• Gynecologic oncology
  Hamilton Chad A., Farley John H., Miller Austin, Miller Caela, Krivak Thomas C., Chernofsky Mildred R., Stany Michael P., Armstrong Deborah K., Rose G. Scott, Markman Maurie, Ozols Robert F., Maxwell G. Larry, The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A gynecologic oncology group study
  122:3, p. 521 - 526 2011
• Journal of clinical oncology
  Oliver K. E., Zhu K., Conrads T. P., Rose G. S., Maxwell G. L., Farley J. H., Enewold L., The presence of racial disparities in histopathologic characteristics of uterine cancer in an equal-access environment
  29:15_suppl, p. 5094 - 5094 2011
• Gynecologic oncology
  Farley John, Sill Michael W., Birrer Michael, Walker Joan, Schilder Russell J., Thigpen J. Tate, Coleman Robert L., Miller Brigitte E., Rose Peter G., Lankes Heather A., Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study
  121:2, p. 303 - 308 2011
• Gynecologic oncology
  Farley John, Rose Peter G., Trial design for evaluation of novel targeted therapies
  116:2, p. 173 - 176 2010
• Cancer
  Farley John H., Birrer Michael, Tian Chunqiao, Rose G. Scott, Brown Carol L., Risinger John I., Thigpen J. Tate, Fleming Gini F., Gallion Holly H., Maxwell G. Larry, Chemotherapy Intensity and Toxicity Among Black and White Women With Advanced and Recurrent Endometrial Cancer A Gynecologic Oncology Group Study
  116:2, p. 355 - 361 2010
• International journal of gynecological cancer
  Na Young-Jeong, Farley John, Zeh Audrey, del Carmen Marcela, Birrer Michael J., Penson Richard, Ovarian Cancer Markers of Response
  19:11 Suppl 2, p. S21 - S29 2009
• Gynecologic oncology
  Farley John, Fuchiuji Sartoru, McGuire William P., Hanjani Parviz, Warshal David, Greer Benjamin E., Belinson Jerome, Birrer Michael J., Hoskins William J., Darcy Kathleen M., Tian Chunqiao, Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study
  113:3, p. 341 - 347 2009
• Journal of clinical oncology
  Farley J. H., Schilder R. J., Coleman R. L., Miller B. E., Thigpen J. T., Sill M., Walker J. L., Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group
  27:15_suppl, p. 5521 - 5521 2009
• Gynecologic oncology
  Hamilton Chad A., Chemofsky Mildred R., Rose G. Scott, Farley John H., Maxwell G. Larry, Bernstein Sarah A., Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
  111:3, p. 530 - 532 2008
• Clinical ovarian cancer and other gynecologic malignancies
  Farley John, Birrer Michael J., CON: Therapy for a Patient with Platinum–Resistant/Refractory Ovarian Cancer Should Not Be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
  1:2, p. 99 - 103 2008
• Gynecologic oncology
  Darcy Kathleen M., Bell Jeffrey G., Brady William E., McBroom John W., Young Robert C., McGuire William P., Linnolia R. Ilona, Hendricks Denver, Bonome Tomas, Farley John H., , Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study
  111:3, p. 487 - 495 2008
• The Surgical clinics of North America
  Stany Michael P., Farley John H., Complications of Gynecologic Surgery
  88:2, p. 343 - 359 2008
• Archives of gynecology and obstetrics
  Parente Lynn, Uyehara Catherine, Larsen Wilma, Farley John, Whitcomb Bradford, Long-term impact of the women's health initiative on HRT
  277:3, p. 219 - 224 2008
• Cell Res
  Farley John, Ozbun Laurent L, Birrer Michael J, Genomic analysis of epithelial ovarian cancer
  18:5, p. 538 - 548 2008
• Journal of reproductive medicine
  Farley John H, Trimble Edward L, Harlan Linda C, Clegg Limin X, Larsen Wilma I, Patterns of Care for Cervical Cancer Patients Treated in the U.S. Military Health Care System
  52:11, p. 1040 - 1045 2007
• Journal of reproductive medicine
  Petersen Maj Scott, Farley John, Belnap Christina, Larsen Wilma I, Grading of squamous dysplasia in endocervical curettage specimens : The case for conservative management of mild endocervical dysplasia
  52:10, p. 917 - 921 2007
• Gynecologic oncology
  Farley John, Christian Michaele C., Birrer Michael J., The future of phase II trials
  103:2, p. 20 - 22 2006
• Gynecologic oncology
  Farley John, Bast Robert C., Birrer Michael J., Biomarkers and clinical trial design
  103:2, p. 3 - 5 2006
• Journal of reproductive medicine
  Farley John H, Alexander Alma, Branch Walter, Larsen Wilma, Zahn Christopher, Harrison Terry A, Nielsen Peter, Homas Dallas, Far forward gynecologic care of the female soldier
  51:1, p. 31 - 35 2006
• Journal of clinical oncology
  Farley J. H., McBroom J., Goo E., Larsen W., Truong V., A randomized double-blind phase II evaluation of the cyclooxygenase-2 protein inhibitor celecoxib in treating severe dysplasia of the cervix
  23:16_suppl, p. 5106 - 5106 2005
• Obstetrics and gynecology (New York. 1953)
  Farley John H, Branch Walter, Heathcock R. Brian, Larsen Wilma, Homas Dallas, Treatment of metastatic gestational choriocarcinoma with oral methotrexate in a combat environment
  105:5, p. 1250 - 1254 2005
• Clinical obstetrics and gynecology
  Farley John, Zahn Christopher M, McBroom John W, Current techniques for the evaluation of abnormal cervical cytology
  48:1, p. 133 - 146 2005
• Gynecologic oncology
  Farley John, Hashiro Glenn, Uyehara Catherine, Belnap Christina, Birrer Michael, Salminen Eric, Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure
  92:2, p. 596 - 602 2004
• Current oncology reports
  Farley John H, Birrer Michael J, Biologic directed therapies in gynecologic oncology
  5:6, p. 459 - 467 2003
• Gynecologic oncology
  Kost Edward R, Nycum Lawrence R, Hall Kevin L, Hines Jeffrey F, Farley John H, Rose G.Scott, Carlson Jay W, Fischer Joseph R, Kendall Brian S, Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer
  89:2, p. 218 - 226 2003
• Cancer research (Chicago, Ill.)
  Farley John, Smith Leia M, Darcy Kathleen M, Sobel Eugene, O'Connor Dennis, Henderson Benita, Birrer Michael J, Morrison Larry E, , Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study
  63:6, p. 1235 - 1241 2003
• Gynecologic oncology
  Nycum L.R., Smith L.M., Farley J.H., Kost E.R., Method M.W., Birrer M.J., The Role of p27 in Endometrial Carcinoma
  81:2, p. 242 - 246 2001
• Cancer
  Farley John H, Kost Edward R, Hines Jeffrey F, Taylor Robert R, Carlson Jay W, Parker Mary F, Rogers Stacey J, Harrison Terry A, Macri Cynthia I, Parham Groesbeck P, Equal care ensures equal survival for African-American women with cervical carcinoma
  91:4, p. 869 - 873 2001
• Obstetrics and gynecology (New York. 1953)
  Farley John, O’Boyle John D, Heaton Jason, Remmenga Stephen, Extraosseous Ewing sarcoma of the vagina
  96:5, p. 832 - 834 2000
• Gynecologic oncology
  Farley John H., Birrer Michael J., Nycum Lawrence R., Park Robert C., Taylor Robert R., Age-Specific Survival of Women with Endometrioid Adenocarcinoma of the Uterus
  79:1, p. 86 - 89 2000
• Gynecologic oncology
  Schmitz Mary Jo, Farley John, Hendricks Denver T., Taylor Robert R., Birrer Michael J., Geradts Joseph, Rose G.Scott, p27 and Cyclin D1 Abnormalities in Uterine Papillary Serous Carcinoma
  77:3, p. 439 - 445 2000
• International journal of gynecological pathology
  Gaertner Erich, Farley John, Taylor Robert, Silver Susan, Collision of Uterine Rhabdoid Tumor and Endometrioid Adenocarcinoma: A Case Report and Review of the Literature
  18:4, p. 396 - 401 1999
• Analytical and quantitative cytology and histology
  Farley J, Taylor R, Gray K, Loup D, Nelson M, Miller M J, Transferrin in normal and neoplastic endocervical tissues: distribution and receptor expression
  20:4, p. 238 - 249 1998
• Gynecologic oncology
  Farley John H., Mcleod David G., Douglas Thomas H., Harrison Charles R., Ureteral Carcinoma Presenting as a Complex Pelvic Mass in a Post Menopausal Patient
  70:1, p. 134 - 136 1998
• Gynecologic oncology
  Farley John H., Taylor Robert R., Cervical Carcinosarcoma Occurring after Subtotal Hysterectomy, a Case Report
  67:3, p. 322 - 324 1997
• Gynecologic oncology
  Farley John H., Bosscher James R., Taylor Robert R., Late Presentation of an α-Fetoprotein Secreting Isolated Large Upper Abdominal Retroperitoneal Sertoli-Leydig Cell Tumor Recurrence
  56:2, p. 319 - 322 1995
• Gynecologic oncology
  Teneriello Michael, O'Connor Dennis, Barnhill Danny, Farley John, Parker Mary, Shaver Timothy, Park Robert, Management of Advanced Ovarian Epithelial Cancer in the Renal Transplant Patient
  50:3, p. 374 - 378 1993
• Military medicine
  Farley John H., Seyfer Alan E., Chest Wall Tumors: Experience with 58 Patients
  156:8, p. 413 - 415 1991
• Military medicine
  Farley J. H, Seyfer A. E, Chestwall tumors : experience with 58 patients
  156:8, p. 413 - 415 1991